Radioconjugate drugs—combining radionuclides with targeting ligands such as antibodies, peptides, or small molecules via chelators and linkers—represent a cutting-edge approach in precision medicine. By delivering radionuclides directly to disease sites, they enable targeted tumor ablation or highly accurate diagnostic imaging, revolutionizing both therapy and diagnostics. To enhance the stability, solubility, and pharmacokinetics of your radioconjugates, Sinopeg offers high-purity, monodisperse polyethylene glycol (PEG) derivatives. These well-defined PEG linkers ensure improved conjugation efficiency, reduced immunogenicity, and optimized in vivo performance—key factors for developing safe and effective radiopharmaceuticals. Whether you are designing novel radioligands or optimizing existing constructs, Sinopeg’s tailored PEG solutions can accelerate your R&D and help bring more precise, impactful treatments to patients. Reach out to explore how we can support your next-generation radioconjugate projects! Various Kingds And Grades Of Such Monodispersed Are Readily Avaliable| SINOPEG

J Exp Med. 2025 Sep 1;222(9):e20241454. doi: 10.1084/jem.20241454. Epub 2025 Jun 6. Membrane-IL12 adjuvant mRNA vaccine polarizes pre-effector T cells for optimized tumor control Abstract Conventional mRNA cancer vaccines can expand the quantity of tumor-specific CD8 T cells, but their effector function might be compromised. Specific cytokine signaling may enhance T cell differentiation for better tumor killing. We screened various cytokines and identified IL-12 as a potent adjuvant for mRNA vaccines, though with significant systemic toxicity. To balance efficacy and toxicity, we developed a membrane-tethered IL-12 (mtIL12) adjuvant mRNA vaccine. This design restricts mtIL12 expression to the surface of antigen-presenting cells, thereby selectively activating antigen-specific T cells without affecting bystander T or NK cells. mtIL12 adjuvant mRNA vaccination induced a unique pre-effector T cell subset that gives rise to highly responsive effector T cells, resulting in superior anti-tumor activity. Moreover, this approach overcame immune checkpoint therapy resistance and prevented cancer metastasis. Our study highlights that next-generation mRNA vaccines encoding membrane-tethered cytokine adjuvants can generate potent effector T cells, offering effective tumor control with reduced toxicity. Product: Wholesale Best Excipient For DNA/RNA Delivery,professional Excipient For DNA/RNA Delivery Suppliers

Bioact Mater. 2024 Jun 21:40:430-444. doi: 10.1016/j.bioactmat.2024.06.021. eCollection 2024 Oct. Kneadable dough-type hydrogel transforming from dynamic to rigid network to repair irregular bone defects Abstract Irregular bone defects, characterized by unpredictable size, shape, and depth, pose a major challenge to clinical treatment. Although various bone grafts are available, none can fully meet the repair needs of the defective area. Here, this study fabricates a dough-type hydrogel (DR-Net), in which the first dynamic network is generated by coordination between thiol groups and silver ions, thereby possessing kneadability to adapt to various irregular bone defects. The second rigid covalent network is formed through photocrosslinking, maintaining the osteogenic space under external forces and achieving a better match with the bone regeneration process. In vitro, an irregular alveolar bone defect is established in the fresh porcine mandible, and the dough-type hydrogel exhibits outstanding shape adaptability, perfectly matching the morphology of the bone defect. After photocuring, the storage modulus of the hydrogel increases 8.6 times, from 3.7 kPa (before irradiation) to 32 kPa (after irradiation). Furthermore, this hydrogel enables effective loading of P24 peptide, which potently accelerates bone repair in Sprague-Dawley (SD) rats with critical calvarial defects. Overall, the dough-type hydrogel with kneadability, space-maintaining capability, and osteogenic activity exhibits exceptional potential for clinical translation in treating irregular bone defects. Keywords: Dough-type hydrogel; Dynamic network; Irregular bone defect; Kneadable; Rigid network. Product: Manufacturer Of PEG Derivative By Structure,Wholesale PEG Derivative By Structure

Pharmaceutics. 2025 Jan 24;17(2):157. doi: 10.3390/pharmaceutics17020157. Engineering Lipid Nanoparticles to Enhance Intracellular Delivery of Transforming Growth Factor-Beta siRNA (siTGF-β1) via Inhalation for Improving Pulmonary Fibrosis Post-Bleomycin Challenge Abstract Background/Objectives: Transforming Growth Factor-beta (TGFβ1) plays a core role in the process of pulmonary fibrosis (PF). The progression of pulmonary fibrosis can be alleviated by siRNA-based inhibiting TGF-β1. However, the limitations of naked siRNA lead to the failure of achieving therapeutic effect. This study aimed to design lipid nanoparticles (LNPs) that can deliver siTGF-β1 to the lungs for therapeutic purposes. Methods: The cytotoxicity and transfection assay in vitro were used to screen ionizable lipids (ILs). Design of Experiments (DOE) was used to obtain novel LNPs that can enhance resistance to atomization shear forces. Meanwhile, the impact of LNPs encapsulating siTGF-β1 (siTGFβ1-LNPs) on PF was investigated. Results: When DLin-DMA-MC3 (MC3) was used as the ILs, the lipid phase ratio was MC3:DSPC:DMG-PEG2000:cholesterol = 50:10:3:37, and N/P = 3.25; the siTGFβ1-LNPs could be stably delivered to the lungs via converting the siTGFβ1-LNPs solution into an aerosol (atomization). In vitro experiments have confirmed that siTGFβ1-LNPs have high safety, high encapsulation, and can promote cellular uptake and endosomal escape. In addition, siTGFβ1-LNPs significantly reduced inflammatory infiltration and attenuated deposition of extracellular matrix (ECM) and protected the lung tissue from the toxicity of bleomycin (BLM) without causing systemic toxicity. Conclusions: The siTGFβ1-LNPs can be effectively delivered to the lungs, resulting in the silencing of TGF-β1 mRNA and the inhibition of the epithelial-mesenchymal transition pathway, thereby delaying the process of PF, which provides a new method for the treatment and intervention of PF. Keywords: design of experiments (DOE); lipid nanoparticles (LNPs); pulmonary fibrosis (PF); siRNA delivery; transforming growth factor β1 (TGF-β1). Product: Wholesale Best Excipient For DNA/RNA Delivery,professional Excipient For DNA/RNA Delivery Suppliers

Recently, SINOPEG's self-developed products, mPEG-DTA-1 and HO-PEG-DTA-5, have been formally granted European patents! This marks the recognition of domestically produced high-end LNP excipients by the international regulatory system, laying a solid foundation for China's innovative drugs to enter the global market! As core components of the LNP delivery system, the structure of PEG lipids decisively influences the safety, stability, and immunogenicity of the formulation. SINOPEG has always been committed to the research and development of new technologies and products, and has already secured a significant position in the field of domestic PEG lipid R&D. The newly authorized mPEG-DTA-1 and HO-PEG-DTA-5 are important achievements of the company's continuous innovation in the PEG lipid field. Innovation Breakthrough: mPEG-DTA-1 and HO-PEG-DTA-5 Granted European Patents HO-PEG-DTA-5 is a PEG lipid containing a hydroxyl terminal, which, together with its structural counterpart mPEG-DTA-1, forms the core layout of SINOPEG's product series in this category. To date, these two products have completed their global intellectual property layout: they obtained Chinese patent authorization back in 2023 (Patent No.: ZL202280003648.7) and recently received European patent authorization. (Screenshot source: European Patent Office, Link: https://register.epo.org/application?number=EP22784092&tab=main) Meanwhile, the independently developed mPEG-DTA-1 has already completed its filing with the CDE (Filing No.: F20230000444) and DMF submission (Filing No.: 039451). Even more encouragingly, HO-PEG-DTA-5 will soon complete dual submissions in China and the US, providing strong excipient support and registration convenience for Chinese innovative pharmaceutical companies aiming for the international mainstream pharmaceutical market! Note: For more product filing information, please feel free to contact us. LNP Technology: A Revolutionary Nano-Delivery Platform Lipid Nanoparticles (LNP), as one of the most successful nano-delivery carriers, have demonstrated exceptional capabilities in delivering cytotoxic chemotherapeutic drugs, antibiotics, and nucleic acid therapeutics. In recent years, with the rapid development of mRNA vaccines and drugs, the importance of LNP technology has become increasingly prominent, making it a focal point in the global pharmaceutical field. The granting of European patents for SINOPEG's products not only reflects the international intellectual property system's recognition of China's innovative achievements but also signifies that Chinese companies are steadily moving towards the center stage in the field of high-end pharmaceutical raw materials, potentially injecting new vitality into the global development of LNP technology. Product Portfolio: Extensive Layout Meets Diverse Needs Leveraging profound technical expertise, SINOPEG has developed a variety of novel PEG-lipid structures, providing more high-quality options for glo...

This golden autumn, SINOPEG ventured to Europe with its innovative products and solutions, making consecutive appearances at two premier international industry exhibitions within two months, engaging in deep exchanges with global pharmaceutical elites. CPHI Frankfurt 2025 (Frankfurt, Germany, Oct 28-30) As the world's largest and most influential professional event for the pharmaceutical industry, CPHI Frankfurt brought together industry elites from across the globe. In this grand gathering, SINOPEG attracted numerous visitors with its professional technical sharing. During the exhibition, we prominently showcased our latest achievements in areas such as in vivo CAR-T delivery, Antibody-Drug Conjugate (ADC) linkers, and block copolymers. We held in-depth discussions with multiple potential clients and partners from Europe, North America, and Asia! Many international clients praised our continuously improving R&D capabilities and product quality control system. TIDES Europe 2025 (Basel, Switzerland, Nov 11-13) Following closely, we moved to Switzerland to participate in TIDES Europe, an exhibition focused on oligonucleotides, peptides, mRNA therapies, and related fields. As one of the fastest-growing segments in biopharmaceuticals, TIDES provided us with a valuable platform for direct dialogue with global top experts. Here, we shared SINOPEG's technical expertise and project experience in fatty acid-modified side chains, LNP delivery material production, and related CMC services, attracting numerous biotechnology companies seeking reliable CDMO partners in this field. Through exchanges with industry benchmark companies, we further clarified our future technological development direction and innovation priorities. The successful participation in these two consecutive exhibitions allowed us to clearly grasp the development pulse of the global pharmaceutical industry chain. We deeply felt that CDMO enterprises from China are increasingly winning the trust of the global market, thanks to their continuously enhancing technical capabilities, flexible service models, and reliable quality systems. Two expeditions, two stages of growth. We brought back customer recognition, partner trust, and market insights – all of which will be invaluable assets for SINOPEG's future development! SINOPEG's journey on the international stage has just begun. We will continue to deepen our core technologies and expand our global footprint. Next year, we will appear on broader international stages, bringing more innovative solutions 'Made in China' to the global pharmaceutical industry. Stay tuned!

Join Us at TIDES Europe 2025 in Congress Center Basel! Mark your calendars!TIDES Europe2025—the premier event for oligonucleotide and peptide therapeutics—is coming to Basel, Switzerland, on 11-13 November 2025. Visit SINOPEG at Booth #333 to explore cutting-edge solutions in: Custom PEG Derivatives (mPEG, heterobifunctional PEGs, branched PEGs) Lipid Nanoparticles (LNPs) & Lipidoids for nucleic acid delivery Innovative Linker Technologies & ADC Payloads Why Stop By? Discuss your formulation challenges with our PEGylation experts Discover high-purity excipients for mRNA, siRNA, and peptide therapies Learn how our GMP-grade materials accelerate preclinical-to-commercial transitions Spotlight Case Study: Ask us about our role in developing temperature-stable LNP formulations for a global COVID-19 vaccine partner! Schedule a 1:1 Meeting: Avoid the crowds—reserve your private session today: sales@sinopeg.com Can't attend? Explore our solutions online: http://www.sinopeg.com Let's shape the future of oligonucleotide and peptide therapeutics together! See you at #333. #TIDES2025 DrugDiscovery #LNPs #mRNA #PeptideTherapeutics #BiotechInnovation

Molecules. 2017 Jul 15;22(7):1190. doi: 10.3390/molecules22071190. Antiviral Lipopeptide-Cell Membrane Interaction Is Influenced by PEG Linker Length Abstract A set of lipopeptides was recently reported for their broad-spectrum antiviral activity against viruses belonging to the Paramyxoviridae family, including human parainfluenza virus type 3 and Nipah virus. Among them, the peptide with a 24-unit PEG linker connecting it to a cholesterol moiety (VG-PEG24-Chol) was found to be the best membrane fusion inhibitory peptide. Here, we evaluated the interaction of the same set of peptides with biomembrane model systems and isolated human peripheral blood mononuclear cells (PBMC). VG-PEG24-Chol showed the highest insertion rate and it was among the peptides that induced a larger change on the surface pressure of cholesterol rich membranes. This peptide also displayed a high affinity towards PBMC membranes. These data provide new information about the dynamics of peptide-membrane interactions of a specific group of antiviral peptides, known for their potential as multipotent paramyxovirus antivirals. Keywords: antiviral; cholesterol; membranes; paramyxoviruses; peptides. PEG Linker: Various Kingds And Grades Of Such Monodispersed Are Readily Avaliable| SINOPEG